190 related articles for article (PubMed ID: 2880242)
1. Detection of factor VIII and IX inhibitors after first exposure to heat-treated concentrates.
Hasegawa DK; Edson JR
Lancet; 1987 Feb; 1(8530):449. PubMed ID: 2880242
[No Abstract] [Full Text] [Related]
2. [The occurrence of immunological tolerance to inhibitors of factors VIII and IX in hemophilia patients].
Brakman GG
Gematol Transfuziol; 1993 Feb; 38(2):18-20. PubMed ID: 8020714
[TBL] [Abstract][Full Text] [Related]
3. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors' Organization (UKHCDO).
Hay CR; Baglin TP; Collins PW; Hill FG; Keeling DM
Br J Haematol; 2000 Oct; 111(1):78-90. PubMed ID: 11091185
[No Abstract] [Full Text] [Related]
4. Serum transfusion in hemophiliacs.
Kimura A
Tohoku J Exp Med; 1973 Oct; 111(2):125-36. PubMed ID: 4784393
[No Abstract] [Full Text] [Related]
5. Hemophilia with factor VIII and factor IX inhibitors, incidence, bleeding problems and management.
Mahasandana C; Patharathienskul D; Suvatte V
Southeast Asian J Trop Med Public Health; 1993; 24 Suppl 1():106-12. PubMed ID: 7886549
[TBL] [Abstract][Full Text] [Related]
6. [Characteristics of the diagnosis, clinical aspects and treatment of hemophilias with specific, circulating anticoagulants].
Barkagan ZS; Sukhoveeva EIa; Eremin GF; Tolochko OI; Shevchenko VI
Probl Gematol Pereliv Krovi; 1972 Apr; 17(4):35-41. PubMed ID: 4680852
[No Abstract] [Full Text] [Related]
7. Factor VIII and IX inhibitors after exposure to heat-treated concentrates.
Pasi KJ; Hamon MD; Perry DJ; Hill FG
Lancet; 1987 Mar; 1(8534):689. PubMed ID: 2882112
[No Abstract] [Full Text] [Related]
8. The prevalence of factor VIII and IX inhibitors among Saudi patients with hemophilia: Results from the Saudi national hemophilia screening program.
Owaidah T; Momen AA; Alzahrani H; Almusa A; Alkasim F; Tarawah A; Nouno RA; Batniji FA; Alothman F; Alomari A; Abu-Herbish S; Abu-Riash M; Siddiqui K; Ahmed M; Mohamed SY; Saleh M
Medicine (Baltimore); 2017 Jan; 96(2):e5456. PubMed ID: 28079788
[TBL] [Abstract][Full Text] [Related]
9. Inhibitors in the Swedish population with severe haemophilia A and B: a 20-year survey.
Knobe KE; Sjörin E; Tengborn LI; Petrini P; Ljung RC
Acta Paediatr; 2002; 91(8):910-4. PubMed ID: 12222714
[TBL] [Abstract][Full Text] [Related]
10. [Circulating anticoagulants during hemophilia].
Josso F; Cosson A; Gazengel C; Allain JP
Rev Fr Transfus; 1972 Dec; 15(4):281-98. PubMed ID: 4659598
[No Abstract] [Full Text] [Related]
11. Physiologic considerations in the management of hemophilia.
Briggs DK
Pathobiol Annu; 1971; 1():205-14. PubMed ID: 4950380
[No Abstract] [Full Text] [Related]
12. Inhibitors in congenital coagulation disorders.
Key NS
Br J Haematol; 2004 Nov; 127(4):379-91. PubMed ID: 15521914
[TBL] [Abstract][Full Text] [Related]
13. Clinical and biological survey of haemophilia A and B patients infused with French heat-treated concentrates.
Parquet A; Boneu B; Bosser C; Cazenave JP; Dirat G; Gazengel G; Grunebaum L; Sultan Y; Verroust F; Wiesel ML
Nouv Rev Fr Hematol (1978); 1988; 30(4):205-7. PubMed ID: 3143099
[TBL] [Abstract][Full Text] [Related]
14. Ineffectiveness of certain commercial prothrombin complex concentrates in treatment of patients with inhibitors of factors VIII and IX.
Penner JA; Abildgaard CF
N Engl J Med; 1979 Mar; 300(10):565-6. PubMed ID: 763264
[No Abstract] [Full Text] [Related]
15. Heat inactivation of human immunodeficiency virus in lyophilized factor VIII and factor IX concentrates.
Piszkiewicz D; Bourret L; Lieu M; Hattley K; Thomas W; Cabradilla CD; Kingdon H; Menache D
Thromb Res; 1987 Jul; 47(2):235-41. PubMed ID: 3116716
[No Abstract] [Full Text] [Related]
16. Development of inhibitors in haemophilia. Ongoing epidemiological study.
Serban M; Mihailov D; Pop L; Ionita H; Ursu E; Talpos-Niculescu S; Ritli L; Baghiu D; Uscatescu V; Petrovanu C; Stancu P; Savescu D; Cucuianu A; Schramm W
Hamostaseologie; 2011 Nov; 31 Suppl 1():S20-3. PubMed ID: 22057218
[TBL] [Abstract][Full Text] [Related]
17. The management of musculoskeletal problems in hemophilia. Part I. Principles of medical management of hemophilia.
McMillan CW; Greene WB; Blatt PM; White GC; Roberts HR
Instr Course Lect; 1983; 32():210-6. PubMed ID: 6443730
[TBL] [Abstract][Full Text] [Related]
18. [Substitution therapy of coagulopathies].
Beeser H; Egli H
Infusionstherapie (1973); 1974 Aug; 1(6):447-53. PubMed ID: 4466806
[No Abstract] [Full Text] [Related]
19. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization.
Collins PW; Chalmers E; Hart DP; Liesner R; Rangarajan S; Talks K; Williams M; Hay CR;
Br J Haematol; 2013 Jan; 160(2):153-70. PubMed ID: 23157203
[No Abstract] [Full Text] [Related]
20. [Transfusion therapy of hemophilia A and B].
Egli H
Bibl Haematol; 1967; 27():204-10. PubMed ID: 5595089
[No Abstract] [Full Text] [Related]
[Next] [New Search]
